NfL — The Universal Biomarker of Axonal Injury

Neurofilament Light chain (NfL) is the smallest subunit of neurofilaments — the type IV intermediate filament proteins that form the primary structural scaffold of the neuronal cytoskeleton. Expressed abundantly in large-caliber myelinated axons, NfL is released into the extracellular space following axonal damage or degeneration, regardless of the underlying etiology. Measurable in both cerebrospinal fluid (CSF) and blood, NfL has emerged as a sensitive, quantitative, and disease-agnostic biomarker of neuronal injury.

Why NfL Is the Most Versatile Neurodegeneration Biomarker

  • Cross-disease applicability: NfL is elevated across a remarkably broad spectrum of neurological conditions — Alzheimer's disease, multiple sclerosis, ALS, frontotemporal dementia, traumatic brain injury, Huntington's disease, Parkinson's disease, and more. This makes it a powerful research tool for studies spanning multiple disease areas.
  • Quantitative injury readout: Blood NfL concentration correlates with the magnitude of axonal damage, providing a continuous, quantitative measure of ongoing neurodegeneration in research settings.
  • Prognostic value: Published studies demonstrate that elevated baseline NfL predicts future brain atrophy, cognitive decline, and disease progression across multiple neurological disorders.
  • Treatment response monitoring: NfL reductions have been observed in response to disease-modifying therapies in multiple sclerosis research, supporting its use as a pharmacodynamic biomarker in therapeutic development programs.
  • Blood-based accessibility: The strong correlation between CSF and blood NfL enables non-invasive, repeat-measure longitudinal research designs that are impractical with lumbar puncture.

Research Applications Across Disease Areas

  • Alzheimer's disease research — NfL complements amyloid and Tau biomarkers by capturing the neurodegenerative component of AD pathology; elevated NfL predicts faster cognitive decline in amyloid-positive research cohorts.
  • Multiple sclerosis research — NfL is one of the most extensively studied blood biomarkers in MS; levels correlate with MRI lesion load, relapse activity, and treatment response to disease-modifying therapies.
  • Amyotrophic lateral sclerosis research — baseline NfL levels correlate with disease progression rate and survival in ALS research cohorts.
  • Frontotemporal dementia research — NfL distinguishes FTD from primary psychiatric disorders and tracks disease intensity in longitudinal observational studies.
  • Traumatic brain injury research — serum NfL reflects the severity of axonal injury following concussion and repetitive head impacts; widely studied in sports-related concussion and military TBI research programs.
  • Cross-disease comparative research — NfL's pan-disease signal enables head-to-head comparisons of neurodegenerative burden across different pathologies in large cohort studies.